Hainan Honz Pharmaceutical Co Market Cap ($319.01 Million)
Market Cap & Net Worth: Hainan Honz Pharmaceutical Co (300086)
Hainan Honz Pharmaceutical Co market cap. Hainan Honz Pharmaceutical Co (SHE:300086) has a market capitalization of $319.01 Million (CN¥2.18 Billion) as of November 5, 2026. Listed on the SHE stock exchange, this China-based company holds position #14259 globally and #4211 in its home market, demonstrating a 0.84% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Hainan Honz Pharmaceutical Co's stock price CN¥4.79 by its total outstanding shares 455124411 (455.12 Million). Also see 300086 cash generation efficiency for how efficiently the company converts equity into cash flow.
Hainan Honz Pharmaceutical Co Market Cap History (2015–2026)
Hainan Honz Pharmaceutical Co market cap history from 2015 to 2026. Data shows change from $1.14 Billion to $319.01 Million (-9.84% CAGR). Check 300086 live share price for real-time trading data and today's change.
Hainan Honz Pharmaceutical Co Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Hainan Honz Pharmaceutical Co's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore 300086 net assets growth trend to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
1.72x
Hainan Honz Pharmaceutical Co's market cap is 1.72 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $902.16 Million | $471.47 Million | $46.16 Million | 1.91x | 19.55x |
| 2017 | $699.95 Million | $668.14 Million | $55.54 Million | 1.05x | 12.60x |
| 2018 | $388.86 Million | $882.74 Million | $13.37 Million | 0.44x | 29.09x |
| 2019 | $349.08 Million | $1.01 Billion | -$26.46 Million | 0.35x | N/A |
| 2020 | $372.97 Million | $921.64 Million | $9.34 Million | 0.40x | 39.94x |
| 2021 | $578.08 Million | $836.57 Million | $10.99 Million | 0.69x | 52.61x |
| 2022 | $414.25 Million | $535.75 Million | -$187.58 Million | 0.77x | N/A |
| 2023 | $390.94 Million | $739.57 Million | $11.53 Million | 0.53x | 33.91x |
| 2024 | $326.34 Million | $472.82 Million | -$216.21 Million | 0.69x | N/A |
| 2025 | $801.19 Million | $466.12 Million | -$230.14 Million | 1.72x | N/A |
Competitor Companies of 300086 by Market Capitalization
Companies near Hainan Honz Pharmaceutical Co in the global market cap rankings as of November 5, 2026. Also see Hainan Honz Pharmaceutical Co balance sheet assets for a full breakdown of the balance sheet.
Key companies related to Hainan Honz Pharmaceutical Co by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #514 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #538 globally with a market cap of $50.42 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #588 globally with a market cap of $45.79 Billion USD ( CN¥312.89 Billion CNY).
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #621 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #514 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #538 | GALDERMA GROUP AG | NYSE:GALDY | $50.42 Billion | $47.80 |
| #588 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $45.79 Billion | CN¥49.05 |
| #621 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €18.50 |
Market Capitalization of Hainan Honz Pharmaceutical Co (2015–2026)
Market capitalization of Hainan Honz Pharmaceutical Co from 2015 to today. Between 2015 and today, Hainan Honz Pharmaceutical Co's market cap moved from $1.14 Billion to $ 319.01 Million, with a yearly change of -9.84%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥319.01 Million | -60.18% |
| 2025 | CN¥801.19 Million | +145.51% |
| 2024 | CN¥326.34 Million | -16.52% |
| 2023 | CN¥390.94 Million | -5.63% |
| 2022 | CN¥414.25 Million | -28.34% |
| 2021 | CN¥578.08 Million | +54.99% |
| 2020 | CN¥372.97 Million | +6.85% |
| 2019 | CN¥349.08 Million | -10.23% |
| 2018 | CN¥388.86 Million | -44.44% |
| 2017 | CN¥699.95 Million | -22.41% |
| 2016 | CN¥902.16 Million | -20.91% |
| 2015 | CN¥1.14 Billion | -- |
End of Day Market Cap According to Different Sources
On Nov 5th, 2026 the market cap of Hainan Honz Pharmaceutical Co was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $319.01 Million USD |
| MoneyControl | $319.01 Million USD |
| MarketWatch | $319.01 Million USD |
| marketcap.company | $319.01 Million USD |
| Reuters | $319.01 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Hainan Honz Pharmaceutical Co
Honz Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sale of pediatric medicines in China and internationally. It operates through Pharmaceutical Manufacturing and Sales; and Daily Necessities Manufacturing and Sales segments. The company offers medicines for children and adults in the areas of anti-anaphylaxis, antidiarrheal, cough … Read more